Literature DB >> 19399945

Serum antibodies positivity to 12 Helicobacter pylori virulence antigens in patients with benign or malignant gastroduodenal diseases--cross-sectional study.

Tajana Filipec Kanizaj1, Miroslava Katicić, Vladimir Presecki, Slavko Gasparov, Vesna Colić Cvrlje, Branko Kolarić, Anna Mrzljak.   

Abstract

AIM: To investigate the association of gastric histological and endoscopic findings in patients with Helicobacter pylori (H. pylori), according to presence of seropositivity to 12 bacterial virulence antigens.
METHODS: This is a cross-sectional single-center study of 360 consecutive outpatients referred in the period of one year to upper gastrointestinal endoscopy because of dyspeptic complaints. Patients sera were tested by Western blot method to determine the presence of serum antibodies to bacterial virulence antigens--p120 (CagA--cytotoxin-associated antigen), p95 (VacA - vacuolating cytotoxin), p67 (FSH--flagellar sheath protein), p66 (UreB--urease enzyme heavy subunit), p57 (HSP homologue--heath shock protein homologue), p54 (flagellin), p33, p30 (OMP--outer membrane protein), p29 (UreA--urease enzyme light subunit), p26, p19, and p17. Upper gastrointestinal endoscopy was performed, endoscopic diagnosis recorded, and 4 mucosal biopsy samples were obtained and assessed according to Updated Sydney protocol.
RESULTS: The sera of 207 patients were analyzed. Thirty patients had gastric adenocarcinoma, 126 peptic ulcers, and 51 normal finding. p120 (CagA) seropositivity was significantly more often present in patients with higher activity grade in the antrum (P = 0.025), p30 in patients with greater inflammation in the antrum (P = 0.025) and the corpus (P = 0.010), p33 in patients with greater inflammation in the corpus (P = 0.050), and p19 (OMP) in patients with lower intestinal metaplasia grades in the corpus (P = 0.025). Seroreactivity to all other bacterial proteins showed no association with the histological status of the stomach mucosa. Except for the seropositivity to protein p95 (VacA), which was more often present in patients with duodenal ulcer (P = 0.006), there was no difference in seroreactivity to other bacterial proteins and upper gastrointestinal endoscopic findings.
CONCLUSIONS: p120 (CagA), p33, p30 (OMP), and p19 (OMP) seropositivity was more often present in patients with higher grades of the histological parameters of gastritis and seropositivity to protein p95 (VacA) with endoscopic presence of duodenal ulcer. Histological parameters of gastritis are more associated with bacterial virulence than endoscopic findings.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19399945      PMCID: PMC2681059          DOI: 10.3325/cmj.2009.50.124

Source DB:  PubMed          Journal:  Croat Med J        ISSN: 0353-9504            Impact factor:   1.351


  41 in total

1.  IgG immune response to Helicobacter pylori antigens in patients with gastric cancer as defined by ELISA and immunoblotting.

Authors:  K Klaamas; M Held; T Wadström; A Lipping; O Kurtenkov
Journal:  Int J Cancer       Date:  1996-07-03       Impact factor: 7.396

2.  The interrelationship between cytotoxin-associated gene A, vacuolating cytotoxin, and Helicobacter pylori-related diseases.

Authors:  J F Weel; R W van der Hulst; Y Gerrits; P Roorda; M Feller; J Dankert; G N Tytgat; A van der Ende
Journal:  J Infect Dis       Date:  1996-05       Impact factor: 5.226

Review 3.  Helicobacter pylori: who is positive and who is not?

Authors:  E J Kuipers; B E Schenk; S G Meuwissen
Journal:  Eur J Gastroenterol Hepatol       Date:  1995-06       Impact factor: 2.566

4.  Relation between IgG and IgA antibody titres against Helicobacter pylori in serum and severity of gastritis in asymptomatic subjects.

Authors:  J Kreuning; J Lindeman; I Biemond; C B Lamers
Journal:  J Clin Pathol       Date:  1994-03       Impact factor: 3.411

5.  Heightened inflammatory response and cytokine expression in vivo to cagA+ Helicobacter pylori strains.

Authors:  R M Peek; G G Miller; K T Tham; G I Perez-Perez; X Zhao; J C Atherton; M J Blaser
Journal:  Lab Invest       Date:  1995-12       Impact factor: 5.662

6.  Antigen recognition during progression from acute to chronic infection with a cagA-positive strain of Helicobacter pylori.

Authors:  H M Mitchell; S L Hazell; T Kolesnikow; J Mitchell; D Frommer
Journal:  Infect Immun       Date:  1996-04       Impact factor: 3.441

7.  Serologic detection of infection with cagA+ Helicobacter pylori strains.

Authors:  T L Cover; Y Glupczynski; A P Lage; A Burette; M K Tummuru; G I Perez-Perez; M J Blaser
Journal:  J Clin Microbiol       Date:  1995-06       Impact factor: 5.948

8.  Serum antibody response to the superficial and released components of Helicobacter pylori.

Authors:  M Bazillou; C Fendri; O Castel; P Ingrand; J L Fauchére
Journal:  Clin Diagn Lab Immunol       Date:  1994-05

9.  Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach.

Authors:  M J Blaser; G I Perez-Perez; H Kleanthous; T L Cover; R M Peek; P H Chyou; G N Stemmermann; A Nomura
Journal:  Cancer Res       Date:  1995-05-15       Impact factor: 12.701

10.  Gene structure of the Helicobacter pylori cytotoxin and evidence of its key role in gastric disease.

Authors:  J L Telford; P Ghiara; M Dell'Orco; M Comanducci; D Burroni; M Bugnoli; M F Tecce; S Censini; A Covacci; Z Xiang
Journal:  J Exp Med       Date:  1994-05-01       Impact factor: 14.307

View more
  2 in total

1.  Antigen-specific humoral responses against Helicobacter pylori in patients with systemic sclerosis.

Authors:  Georgios Efthymiou; Christos Liaskos; Theodora Simopoulou; Emmanouela Marou; Eleni Patrikiou; Thomas Scheper; Wolfgang Meyer; Dimitrios Daoussis; Lazaros I Sakkas; Dimitrios P Bogdanos
Journal:  Immunol Res       Date:  2020-02       Impact factor: 2.829

Review 2.  Vacuoles of Candida yeast as a specialized niche for Helicobacter pylori.

Authors:  Farideh Siavoshi; Parastoo Saniee
Journal:  World J Gastroenterol       Date:  2014-05-14       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.